Ribavirin priming in patients with chronic hepatitis C and normal ALT: A pilot study

Hepato-Gastroenterology

Volumn 55, Issue 86-87, 2008, Pages 1666-1670

  Töx, Ulrich ^a   Schulte, Sigrid ^a   Heindl, Björn ^a   Goeser, Tobias ^a   Drebber, Uta ^b   Stelzer, Annette ^a   Steffen, Hans Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chronic hepatitis C; Cytokines; Normal ALT; Peginterferon alpha 2b; Ribavirin priming; Sequential therapy; TH2 TH1 shift

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTHRALGIA; ARTICLE; AUTOIMMUNE THYROIDITIS; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; HYPOTENSION; HYPOTHYROIDISM; INJECTION SITE ABSCESS; LIVER BIOPSY; LYMPHOCYTE; MALE; MONOTHERAPY; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; SUPERNATANT;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CYTOKINES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RIBAVIRIN; TH1 CELLS; TH2 CELLS;

EID: 57049088596     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Anonymous: Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6:35-47.
2. Hayashi N, Takehara T: Antiviral therapy for chronic hepatitis C: Past, present, and future. J Gastroenterol 2006; 41:17-27.
3. Poynard T, Marcellin P, Lee SS, et al: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
4. McHutchison JG, Gordon SC, Schiff ER, et al: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
5. Davis GL, Esteban-Mur R, Rustgi V, et al: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1493-1499.
6. Reichard O, Norkrans G, Fryden A, et al: Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351:83-87.
7. Tam RC, Pai B, Bard J, et al: Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 1999; 30:376-382.
8. Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215-229.
9. Cramp ME, Rossol S, Chokshi S, et al: Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118:346-355.
10. Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, et al: Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. Rev Invest Clin 2003; 55:138-142.
11. Carlsson T, Reichard O, Norkrans G, et al: Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005; 12:473-480.
12. von Wagner M, Huber M, Berg T, et al: Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-527.
13. Napoli N, Giannelli G, Parisi CV, et al: Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiol 2005; 28:13-21.
14. Ferenci P, Fried MW, Shiffman ML, et al: Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43:425-433.
15. Keating GM, Plosker GL: Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels. Drugs 2005; 65:521-536.
16. Krajden M, Ziermann R, Khan A, et al: Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay. J Clin Microbiol 2002; 40:2903-2907.
17. Elbeik T, Surtihadi J, Destree M, et al: Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol 2004; 42:563-569.
18. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-1520.
19. Gordon SC, Fang JW, Silverman AL, McHutchison JG, Albrecht JK: The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000; 32:400-404.
20. Bacon BR: Chronic hepatitis C and normal ALT: considerations for treatment. Am J Gastroenterol 2004; 99:1706-1707.
21. Hui CK, Belaye T, Montegrande K, Wright TL: A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003; 38:511-517.
22. Mathurin P, Moussalli J, Cadranel JF, et al: Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27:868-872.
23. Sangiovanni A, Morales R, Spinzi G, et al: Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998; 27:853-856.
24. Pradat P, Alberti A, Poynard T, et al: Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36:973-977.
25. Zeuzem S, Diago M, Gane E, et al: Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127:1724-1732.
26. Shiffman ML, Stewart CA, Hofmann CM, et al: Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis 2000; 182:1595-1601.
27. Jacobson IM, Ahmed F, Russo MW, et al: Interferon alfa-2b [correction of alpha-2b] and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol 2004; 99:1700-1705.
28. Hultgren C, Milich DR, Weiland O, Sallberg M: The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79 (Pt 10):2381-2391.
29. Fang SH, Hwang LH, Chen DS, Chiang BL: Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 2000; 33:791-798.
30. Shiina M, Kobayashi K, Satoh H, et al: Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C. J Gastroenterol Hepatol 2004; 19:558-564.
31. Woitas RP, Lechmann M, Jung G, et al: CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997; 159:1012-1018.
32. Jessner W, Gschwantler M, Steindl-Munda P, et al: Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358:1241-1242.
33. Furusyo N, Kubo N, Toyoda K, et al: Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. Antiviral Res 2005; 67:46-54.
34. Pawlotsky JM, Dahari H, Neumann AU, et al: Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126:703-714.
35. Khakoo S, Glue P, Grellier L, et al: Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46:563-570.
36. Jen JF, Glue P, Gupta S, Zambas D, Hajian G: Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22:555-565.
37. Tsubota A, Akuta N, Suzuki F, et al: Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology 2002; 45:33-42.
38. Arase Y, Ikeda K, Tsubota A, et al: Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005; 48:138-144.
39. Lindahl K, Stable L, Bruchfeld A, Scbvarcz R: High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41:275-279.
40. Dixit NM, Perelson AS: The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 2006; 63:832-842.